RESEARCH RESULTS

RESEARCH FOCUS

Investigate the role of the microbiota in digestive system cancers, metabolic syndrome, and rare metabolic disorders, as well as their pathogenic mechanisms. Develop microbiota-centered biomarkers and intervention strategies.
Using the microbiota as the core, conduct multiomics and phenomics research on the mentioned diseases and their sub-healthy populations. Establish their digital avatars for disease prediction and prevention.
The research mentioned above aims to develop a precision health research and development ecosystem that encompasses industry, academia, and research. This will expand the value of research and innovation from basic to clinical, from laboratory to patient care in hospital wards, and from hospitals to the community.

Recent Paper Publications

Publication Date作者論文名稱Abstract期刊名稱SCI Impact Factor
2025年04月(Accepted)吳俊穎教授與林騰立同學等人Psoriasis risk in atopic dermatitis patients treated with dupilumab: a population-based cohort study.JAMA Dermatology11.5
2025年04月17日吳俊穎教授與林騰立同學等人Cardiovascular disease risk in patients with psoriasis receiving biologics targeting本研究發現,相較於口服藥物,使用生物製劑治療的乾癬患者,其心血管疾病風險顯著較低。特別是使用抗TNF-α、抗IL-17與抗IL-23藥物的患者,與較低的心血管疾病風險相關,但抗IL-12/23則無顯著差異。這些結果在不同年齡、性別、地區與共病族群中皆具一致性,支持生物製劑在乾癬治療中對心血管健康的潛在益處。PLOS Medicine10.5
2025年04月07日吳俊穎教授等人The development of live biotherapeutic products: a position statement of Asia-Pacific Microbiota Consortium.本研究由亞太地區的腸道菌相專家就活性生物治療產品(LBP)的開發提出共識建議,涵蓋開發動機、前臨床研究與臨床準備三大面向。專家建議優先使用來源於人體與食物的菌株,並強調開發過程需嚴格進行功能評估、遺傳監控與安全性測試。臨床試驗應精心設計並落實風險管理,以確保產品的安全性與有效性。Gastroenterology & Hepatology23.0
2025年01月高正彥老師等人An Integrated Platform for Investigating Drug-Microbial Interactions to Support Pharmacomicrobiomics StudiesTalanta
2024年12月吳莉玲老師等人Interleukin-1R1 deficiency worsens hepatocellular carcinoma while gemcitabine treatment alleviates the hepatocellular carcinoma-induced increase in intra-hepatic immune cells.J Gastroenterol Hepatol.
2024年11月28日吳俊穎教授與林騰立同學等人Dupilumab impact on psychiatric and sleep disorder risk reduction in atopic dermatitis: A population-based cohort study本研究發現,相較於傳統治療藥物,使用Dupilumab治療異位性皮膚炎的患者在三年內罹患焦慮、憂鬱、適應障礙與睡眠障礙的風險顯著較低。這些結果在不同年齡、性別、種族與共病群體中皆一致,尤其在非裔美國人族群中效果更為明顯。唯有注意力不足過動症的風險差異不具統計顯著性。Ann Allergy Asthma Immunol5.8
2024年7 月30日吳俊穎教授等人Short-chain fatty acids ameliorate imiquimod-induced skin thickening and IL-17 levels and alter gut microbiota in mice: a metagenomic association analysis本研究探討短鏈脂肪酸(SCFAs)對患有類銀屑病的老鼠皮膚表型、全身性炎症及腸道菌群的影響。使用咪唑(IMQ)處理的小鼠作為模型,並進行基因組學研究,分析SCFAs或抗IL-17抗體對皮膚厚度、炎症指標和糞便微生物的影響。結果顯示,SCFAs改善了IMQ誘導的皮膚增厚、脾臟增重及血清IL-17F水平,效果與抗IL-17治療相似。SCFAs還提高了微生物多樣性,並改變了腸道菌群組成,預示著其與糖類降解及苯丙氨酸代謝等過程有關。Scientific reports